2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Arthritis Care and Research

Volumn 64, Issue 5, 2012, Pages 625-639

  Singh, Jasvinder A ^a   Furst, Daniel E ^b   Bharat, Aseem ^a   Curtis, Jeffrey R ^a   Kavanaugh, Arthur F ^c   Kremer, Joel M ^d   Moreland, Larry W ^e   O'Dell, James ^f   Winthrop, Kevin L ^g   Beukelman, Timothy ^a   Bridges, S Louis ^a   Chatham, W Winn ^a   Paulus, Harold E ^b   Suarez Almazor, Maria ^h   Bombardier, Claire ⁱ   Dougados, Maxime ^j   Khanna, Dinesh ^k   King, Charles M ^l   Leong, Amye L ^m   Matteson, Eric L ⁿ   Schousboe, John T ^o   Moynihan, Eileen ^p   Kolba, Karen S ^q   Jain, Archana ^a   Volkmann, Elizabeth R ^b   Agrawal, Harsh ^b   Bae, Sangmee ^b   Mudano, Amy S ^a   Patkar, Nivedita M ^a   Saag, Kenneth G ^a   more..

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j University of Michigan ^*  (France)

^k UNIVERSITY OF MICHIGAN   (United States)

^l NORTH MISSISSIPPI MEDICAL CENTER   (United States)

^m HEALTHY MOTIVATION   (United States)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF MINNESOTA   (United States)

^p Highmark Medicare Services   (United States)

^q Pacific Arthritis Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ARTICLE; DRUG USE; HUMAN; KNOWLEDGE; MEDICAL PRACTICE; MEDICAL SCHOOL; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; WESTERN HEMISPHERE; MEDICAL SOCIETY; REVIEW; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84859832981     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21641     Document Type: Article

References (45)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
2. McGory ML, Shekelle PG, Rubenstein LZ, Fink A, Ko CY. Developing quality indicators for elderly patients undergoing abdominal operations. J Am Coll Surg 2005;201:870-83. (Pubitemid 41689316)
3. Shekelle P. The appropriateness method. Med Decis Making 2004;24:228-31. (Pubitemid 38391941)
4. Shekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ. Sensitivity and specificity of the RAND/UCLA Appropriateness Method to identify the overuse and underuse of coronary revascularization and hysterectomy. J Clin Epidemiol 2001;54:1004-10. (Pubitemid 32888367)
5. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;1:CD008341.
6. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;7:CD008331.
7. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
8. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Galvez Munoz JG, Saiz Cuenca ES, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2009;2:CD007649.
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
10. FDA, US Department of Health and Human Services. What is a serious adverse event? 2011. URL: http://www.fda.gov/ safety/medwatch/howtoreport/ ucm053087.htm.
11. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
12. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984;4:430-5. (Pubitemid 14116643)
13. Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999; 22:385-90. (Pubitemid 29264914)
14. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Mortal Morb Wkly Rep 2000;49: 1-51.
15. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al, and the Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59: 1467-74.
16. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375-82.
17. Han C, Smolen J, Kavanaugh A, St.Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum 2008;59:510-4. (Pubitemid 351563533)
18. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206-15. (Pubitemid 351284438)
19. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
20. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
21. Van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68:1153-8.
22. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;22:1586-93. (Pubitemid 32162981)
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
25. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
26. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44. (Pubitemid 43290588)
27. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36. (Pubitemid 41369090)
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
29. Pincus T. The American College of Rheumatology (ACR) core data set and derivative "patient only" indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl:S109-13. (Pubitemid 46661467)
30. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24. (Pubitemid 41429036)
31. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5. (Pubitemid 41780656)
32. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873-9. (Pubitemid 41798226)
33. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007;26:201-4. (Pubitemid 46020244)
34. Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 2007;26:538-45. (Pubitemid 46359294)
35. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
36. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6. (Pubitemid 36135386)
37. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30. (Pubitemid 36469733)
38. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977;36:71-3. (Pubitemid 8038409)
39. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
40. Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol Suppl 2002;65:39-43. (Pubitemid 34988681)
41. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
42. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol 2007;21:755-87. (Pubitemid 47163602)
43. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
44. Fransen J, Stucki G, van Riel PL. Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003;49 Suppl:S214-24.
45. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. (Pubitemid 36305610)